ABBV
AbbVie Inc.
NYSE: ABBV · North Chicago, IL · Healthcare
$205.12+1.41 (+0.69%)Closed
Market Cap$362.69B
Cash$5.23Bmost recent
Runwayprofitable
P/E (TTM)86.9EPS $2.36
52-Wk Range$168.30 – $238.71
Avg Volume6.3M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$205.12+30.7%
Pipeline
Drug candidates sponsored by AbbVie · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | Lopinavir/Ritonavir | HIV Infection | Completed | 2008-01past | 1 | |
| Phase 4 | methotrexate (MTX) | Psoriatic Arthritis | Completed | 2019-09-23past | 1 | |
| Phase 4 | Upadacitinib | Atopic Dermatitis+4 more | Recruiting | 2029-06 | 5 | |
| Phase 3 | ABT-450/r/ABT-267, ABT-333 | Chronic Hepatitis C Infection | Completed | 2013-12past | 1 | |
| Phase 3 | ABT-493 coformulated with ABT-530 | Hepatitis C Virus Infection+3 more | Completed | 2017-03-15past | 1 | |
| Phase 3 | Palivizumab | Respiratory Syncytial Virus (RSV) | Completed | 2017-07-13past | 1 | |
| Phase 3 | Atrasentan | Diabetic Nephropathy | Terminated | 2018-03-29past | 1 | |
| Phase 2 | Ombitasvir/paritaprevir/ritonavir | Chronic Hepatitis C Infection | Completed | 2020-11-19past | 1 | |
| Phase 3 | Cariprazine | Major Depressive Disorder+3 more | Completed | 2022-09-05past | 2 | |
| Phase 2 | risankizumab IV | Ulcerative Colitis (UC) | Completed | 2022-11-09past | 1 | |
| Phase 3 | adalimumab | Ulcerative Colitis+2 more | Completed | 2024-02-01past | 2 | |
| Phase 3 | Linaclotide | Functional Constipation+1 more | Completed | 2024-05-20past | 1 | |
| Phase 3 | AGN-151586 | Glabellar Lines | Completed | 2025-02-26past | 1 | |
| Phase 3 | Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) | Irritable Bowel Syndrome With Constipation+1 more | Completed | 2025-06-05past | 1 | |
| Phase 3 | Unnamed | Facial Volume Deficit | Completed | 2025-12-05past | 1 | |
| Phase 3 | ABBV-951 | Parkinson's Disease (PD) | Active, not recruiting | 2026-04past | 1 | |
| Phase 3 | Lutikizumab | Hidradenitis Suppurativa | Recruiting | 2026-12 | 1 | |
| Phase 3 | Ubrogepant | Migraine | Recruiting | 2027-06 | 2 | |
| Phase 3 | Venetoclax | Chronic Lymphocytic Leukemia+7 more | Active, not recruiting | 2027-08 | 3 | |
| Phase 3 | Unnamed | Breast Reconstruction | Recruiting | 2029-12 | 1 | |
| Phase 2 | Telisotuzumab Adizutecan | Non-Small Cell Lung Cancer | Recruiting | 2030-09 | 1 | |
| Phase 1 | ABT-751 | Lung Cancer+2 more | Completed | 2009-01past | 1 | |
| Phase 2 | ABT-072 | Hepatitis C Virus Infection | Completed | 2010-04past | 1 | |
| Phase 2 | ABT-450 | Chronic Hepatitis C Infection+2 more | Completed | 2013-05past | 2 | |
| Phase 2 | Adalimumab, current formulation | Rheumatoid Arthritis | Completed | 2013-05past | 1 | |
| Phase 2 | ABT-126 | Schizophrenia | Completed | 2014-11past | 2 | |
| Phase 2 | temozolomide | Melanoma+2 more | Completed | 2016-01past | 1 | |
| Phase 2 | ABT-122 | Rheumatoid Arthritis | Completed | 2016-05past | 1 | |
| Phase 1 | ABT-263 | Chronic Lymphoid Leukemia+5 more | Completed | 2016-10past | 1 | |
| Phase 2 | ABT-199 (Main Cohort) | Chronic Lymphocytic Leukemia+2 more | Completed | 2020-10-28past | 1 | |
| Phase 2 | Ravagalimab 600 mg | Ulcerative Colitis (UC) | Completed | 2021-04-05past | 1 | |
| Phase 2 | ABBV-576 | Cystic Fibrosis (CF) | Terminated | 2023-06-05past | 1 | |
| Phase 2 | ABBV-4083 | Onchocerciasis | Terminated | 2023-08-29past | 1 | |
| Phase 1 | IMGN632 | Blastic Plasmacytoid Dendritic Cell Neoplasm+1 more | Active, not recruiting | 2023-09-06past | 1 | |
| Phase 2 | elezanumab | Multiple Sclerosis (MS)+1 more | Completed | 2024-04-18past | 2 | |
| Phase 2 | Budigalimab | Human Immuno-deficiency Virus (HIV) Disease | Terminated | 2025-09-22past | 1 | |
| Phase 2 | Risankizumab | Hidradenitis Suppurativa+2 more | Not yet recruiting | 2027-01 | 3 | |
| Phase 1 | Azacitidine | Acute Myeloid Leukemia | Active, not recruiting | 2027-02 | 1 | |
| Phase 2 | ABBV-706 | Small Cell Lung Cancer | Recruiting | 2029-05 | 1 | |
| Phase 2 | ABBV-CLS-628 | Autosomal Dominant Polycystic Kidney Disease | Recruiting | 2029-08 | 1 | |
| Phase 1 | ABBV-453 | Multiple Myeloma | Recruiting | 2030-12 | 1 | |
| Phase 1 | ABBV-383 (Etentamig) | Immunoglobulin Light Chain (AL) Amyloidosis | Recruiting | 2031-09 | 1 | |
| Phase 1 | ABBV-257 | Rheumatoid Arthritis | Completed | 2016-02past | 1 | |
| Phase 1 | duvelisib | Lymphoma | Completed | 2016-12past | 1 | |
| Phase 1 | ABT-700 | Advanced Solid Tumors | Completed | 2017-04-27past | 1 | |
| Phase 1 | ABBV-8E12 | Progressive Supranuclear Palsy (PSP) | Completed | 2019-11-20past | 1 | |
| Phase 1 | Veliparib, capsule | Cancer - Ovarian | Withdrawn | 2021-11-16past | 1 | |
| Phase 1 | ABBV-623 | B-cell Lymphoma | Terminated | 2023-01-11past | 1 | |
| Phase 1 | Emraclidine | Renal Impairment | Completed | 2024-12-19past | 1 | |
| Phase 1 | ABBV-141 | Healthy Volunteers | Completed | 2024-12-30past | 1 | |
| Phase 1 | Eftozanermin alfa | Multiple Myeloma | Terminated | 2025-05-05past | 1 | |
| Phase 1 | ABBV-932 | Healthy Volunteers | Completed | 2025-05-26past | 1 | |
| Phase 1 | GUB014295 | Healthy Volunteers+1 more | Completed | 2026-01-05past | 1 | |
| Phase 1 | ABBV-722 | Healthy Volunteer | Recruiting | 2026-04past | 1 | |
| Phase 1 | ABBV-744 | Myelofibrosis (MF) | Active, not recruiting | 2027-01 | 1 | |
| Phase 1 | Livmoniplimab | Advanced Solid Tumors Cancer | Active, not recruiting | 2027-06 | 1 | |
| Phase 1 | Pivekimab Sunirine | Acute Myeloid Leukemia | Not yet recruiting | 2028-04 | 1 | |
| N/A | Unnamed | Kidney Failure, Chronic | Completed | 2011-11past | 1 | |
| N/A | Unnamed | Chronic Kidney Failure+1 more | Completed | 2012-01past | 1 | |
| N/A | Unnamed | Secondary Hyperparathyroidism | Completed | 2013-01past | 1 | |
| N/A | Unnamed | Respiratory Syncytial Virus Infection | Completed | 2013-08past | 1 | |
| N/A | Unnamed | Severe Crohn's Disease+1 more | Completed | 2013-10past | 1 | |
| N/A | Unnamed | Rheumatoid Arthritis+1 more | Completed | 2014-05past | 1 | |
| N/A | Unnamed | Moderate-to-severe Chronic Plaque Psoriasis | Completed | 2014-09past | 1 | |
| N/A | Unnamed | Moderate-to-severe Rheumatoid Arthritis | Completed | 2014-12past | 1 | |
| N/A | Unnamed | Ankylosing Spondylitis | Completed | 2015-10past | 1 | |
| N/A | Unnamed | Pediatric Crohn's Disease | Completed | 2017-05-31past | 1 | |
| N/A | Unnamed | Psoriasis | Completed | 2019-08-06past | 1 | |
| N/A | Unnamed | Spondylarthritis+2 more | Completed | 2019-10-16past | 1 | |
| N/A | Unnamed | Crohn's Disease | Completed | 2020-03-11past | 1 | |
| N/A | Unnamed | HIV-1 Infection | Terminated | 2020-07-08past | 1 | |
| N/A | Unnamed | Endometriosis+2 more | Terminated | 2020-11-19past | 1 | |
| N/A | Unnamed | Hepatitis C Virus (HCV) | Completed | 2021-06-24past | 1 | |
| N/A | Unnamed | Chronic Lymphocytic Leukemia (CLL) | Terminated | 2021-11-09past | 1 | |
| N/A | Unnamed | Hidradenitis Suppurativa (HS) | Completed | 2021-11-10past | 1 | |
| N/A | Unnamed | Ulcerative Colitis (UC) | Completed | 2023-12-15past | 1 | |
| N/A | Unnamed | Atopic Dermatitis | Completed | 2024-11-02past | 1 | |
| N/A | Unnamed | Acute Myeloid Leukemia | Recruiting | 2026-12 | 1 | |
| N/A | Unnamed | Ulcerative Colitis | Recruiting | 2026-12 | 1 | |
| N/A | Unnamed | Parkinson Disease | Recruiting | 2027-06 | 1 | |
| N/A | Unnamed | Atopic Dermatitis | Active, not recruiting | 2027-09 | 1 | |
| N/A | ABBV-787 | Acute Myeloid Leukemia | No Longer Available | — | 1 | |
| N/A | Bimatoprost Sustained Release Implant | Open-angle Glaucoma | No Longer Available | — | 1 | |
| N/A | Navitoclax | Myelofibrosis+2 more | No Longer Available | — | 1 | |
| N/A | rovalpituzumab tesirine | Small Cell Lung Cancer | No Longer Available | — | 1 | |
| N/A | ABT-414 | Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis | No Longer Available | — | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for ABBV. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.